A poor metabolizer for cytochromes P450 2D6 and 2C19: A case report on antidepressant treatment

CNS Spectrums

Volumn 11, Issue 10, 2006, Pages 757-760

  Johnson, Maria ^a   Markham Abedi, Courtney ^b,c,d   Susce, Margaret T ^c   Murray Carmichael, Elaina ^c,e   McCollum, Stuart ^c   De Leon, Jose ^b,c,d,f,g,h  

^a Eastern State Hospital   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c Mental Health Research Center   (United States)

^d EASTERN STATE HOSPITAL   (United States)

^e UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^f University of Kentucky   (United States)

^g Federico Oloriz Neuroscience Institute   (United States)

^h UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; ESCITALOPRAM; MIRTAZAPINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; CLINICAL PRACTICE; DEPRESSION; DRUG METABOLISM; ENZYME METABOLISM; ETHNIC DIFFERENCE; EXTRAPYRAMIDAL SYMPTOM; GENOTYPE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNITED STATES;

EID: 33750017284     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900014887     Document Type: Article

References (16)

1. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyan-Schmiedberg's Arch Pharmacol. 2004;369:89-104.
2. Rogers JF, Nafziger AN, Bertino JS. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 2002;113:746-750.
3. de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics. 2005;46:262-273.
4. Brosen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004;59:5-12.
5. Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundamental Clin Pharmacol. 2003;17:517-538.
6. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473.
7. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for using pharmacogenetic testing of CYP450 2D6 and CYP450 2C19 in psychiatry. Psychosomatics. 2006;47:75-85.
8. Mrazek DA, Smoller JW, de Leon J. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. CNS Spectr. 2006;11(suppl 3):1-13.
9. de Leon J. The AmpliChip CYP450 Test: personalized medicine has arrived in psychiatry. Exp Rev Mol Diagn. 2006;6:277-286.
10. Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet. 2000;38:661-674.
11. Steimer W, Zopf K, von Amelunxen S, et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chemistry. 2005;51:376-385.
12. Reis M, Lundmark J, Bjork H, Bengtsson F. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit. 2002;24:545-553.
13. Rudberg I, Hendset M, Uthus LH, Molden E, Refsum H. Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram). Ther Drug Monit. 2006;28:102-105.
14. von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos. 2001;29:1102-1109.
15. Kirchheiner J, Henckel HB, Meineke I, Roots I, Brockmoller J. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol. 2004;24:647-652.
16. de Leon J, Susce MT, Pan RM, Fairchild M, Koch W, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66:15-27.